Safety and Efficacy of Common Endoscopic Treatments in Patients with Decompensated Liver Cirrhosis

Abstract

BackgroundThe safety and efficacy has always been a concern, when patients with decompensated liver cirrhosis (DLC) receive endoscopic treatments. Methods We performed a retrospective study to evaluate the safety and efficacy of common endoscopic treatments including endoscopic resection (ER) and endoscopic retrograde cholangiopancreatography (ERCP) applying to patients with DLC. Results81 patients received ER (43 endoscopic mucosal resection (EMR) and 38 endoscopic submucosal dissection (ESD)) and 131 patients were treated by ERCP. There were no significant differences of the rate of degeneration and invariability of Child-Pugh (CP) class and the overall rate of adverse events between two groups (93.8%/8.6% ER vs. 96.2%/15.3% ERCP). Both the degeneration rate of CP class (35.4%) and the rate of adverse events (27.1%) in subgroup C of ERCP group was significantly higher (P=0). The rate of poor outcomes was higher in ERCP group (12.2%) than that in ER group (2.5%) (P=.02). And subgroup C of ERCP group had a higher poor outcome rate (27.1%) (P=0).ConclusionsER and ERCP could remove focal lesions or relieve symptoms induced by targeted diseases without significant changes of CP class. Significant benefits and risks coexisted in CP class C patients with DLC when receiving ERCP.